Medika has identified Vitaccess for our Healthcare Innovation watch list. This UK based Digital Startup offers innovative and exciting approaches to data management that directly benefit patient outcomes.
A.I. is critical to the growth of healthcare in the coming decade. It needs to be managed correctly and urgent ethical guidelines regulating its use need to be implimented.
If American healthcare does not start cleaning house to enable digital innovation, it will pay the price, and inevitably, the patient will as always, be the real victim.
Outside the pandemic, “investigational” remains payer code for denying reimbursement. In the case of treatment for chronic conditions, even FDA-approved digital-health and connected devices languish on waitlists for formulary inclusion.
Technology means we no longer need to be separated from our point of care. It can follow us everywhere, an ever-vigilant protector and guardian angel, and its applications are limitless
Outside the pandemic, “investigational” remains payer code for denying reimbursement. In the case of treatment for chronic conditions, even FDA-approved digital-health and connected devices languish on waitlists for formulary inclusion.
Technology means we no longer need to be separated from our point of care. It can follow us everywhere, an ever-vigilant protector and guardian angel, and its applications are limitless
Medika has identified Vitaccess for our Healthcare Innovation watch list. This UK based Digital Startup offers innovative and exciting approaches to data management that directly benefit patient outcomes.
If American healthcare does not start cleaning house to enable digital innovation, it will pay the price, and inevitably, the patient will as always, be the real victim.
A.I. is critical to the growth of healthcare in the coming decade. It needs to be managed correctly and urgent ethical guidelines regulating its use need to be implimented.
Technology means we no longer need to be separated from our point of care. It can follow us everywhere, an ever-vigilant protector and guardian angel, and its applications are limitless
Outside the pandemic, “investigational” remains payer code for denying reimbursement. In the case of treatment for chronic conditions, even FDA-approved digital-health and connected devices languish on waitlists for formulary inclusion.
